Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease

T Lymphocytes Expressing AlphaE Beta7 Integrin in Ulcerative Colitis: Associations With Cellular Lineage and Phenotype

(2017) Christopher A Lamb et al.   Journal of Crohns & Colitis

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

(2016) Gaik W. Tew et al.   GASTROENTEROLOGY

Blockade of αEβ7 integrin suppresses accumulation of CD8+and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo

(2016) Sebastian Zundler et al.   GUT

Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis

(2016) Xiaohui Wei et al.   JOURNAL OF CLINICAL PHARMACOLOGY

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab

(2016) Tim Wyant et al.   Journal of Crohns & Colitis

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database

(2015) Megan E. McAuliffe et al.   CURRENT MEDICAL RESEARCH AND OPINION

Essential role for CD103+ cells in the pathogenesis of spondyloarthritides

(2015) Jean-Marie Berthelot et al.   JOINT BONE SPINE

Review article: anti-adhesion therapies for inflammatory bowel disease

(2014) T. Lobatón et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Distinct Chemokine Signaling Regulates Integrin Ligand Specificity to Dictate Tissue-Specific Lymphocyte Homing

(2014) Hao Sun et al.   DEVELOPMENTAL CELL

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

(2014) Katharina Gerlach et al.   NATURE IMMUNOLOGY

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

(2014) Leon P McLean et al.   Expert Review of Gastroenterology & Hepatology

Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12- and IL-15-Responsive IFN-γ-Producing Cells

(2013) Anja Fuchs et al.   IMMUNITY

Dietary gluten triggers concomitant activation of CD4+ and CD8+    T cells and    T cells in celiac disease

(2013) A. Han et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

(2012) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

(2012) Paul J Rutgeerts et al.   GUT

Distribution and Compartmentalization of Human Circulating and Tissue-Resident Memory T Cell Subsets

(2012) Taheri Sathaliyawala et al.   IMMUNITY

Inhibition of Selective Adhesion Molecules in Treatment of Inflammatory Bowel Disease

(2012) Nilanjan Ghosh et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Ulcerative colitis

(2012) Ingrid Ordás et al.   LANCET

The Yin and Yang of Immunomodulatory Biologics: Assessing the Delicate Balance between Benefit and Risk

(2012) Dimitry M. Danilenko et al.   TOXICOLOGIC PATHOLOGY

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

(2011) EG Stefanich et al.   BRITISH JOURNAL OF PHARMACOLOGY

Progressive Multifocal Leukoencephalopathy and Newer Biological Agents

(2010) Joseph R. Berger   DRUG SAFETY

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

(2010) Gert Van Assche et al.   Journal of Crohns & Colitis

Natalizumab treatment reduces endothelial activity in MS patients

(2010) Alban Millonig et al.   JOURNAL OF NEUROIMMUNOLOGY

The Natural History of Adult Crohn's Disease in Population-Based Cohorts

(2009) Laurent Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Management of Crohn's Disease in Adults

(2009) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

CNS Elevation of Vascular and Not Mucosal Addressin Cell Adhesion Molecules in Patients with Multiple Sclerosis

(2009) Rachel Allavena et al.   AMERICAN JOURNAL OF PATHOLOGY

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

(2009) ET Morgan   CLINICAL PHARMACOLOGY & THERAPEUTICS

Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention

(2009) G. Gorfu et al.   CURRENT MOLECULAR MEDICINE

Anti-integrin monoclonal antibodies

(2009) A. Byron et al.   JOURNAL OF CELL SCIENCE

α4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions

(2009) Shumei Man et al.   JOURNAL OF NEUROIMMUNOLOGY

CCL25 and CCL28 promote α4β7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow

(2008) Alice Miles et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT